FDA Approves Zepbound (Tirzepatide) as the First Medication for Treating Obstructive Sleep Apnea (OSA)
On December 20, 2024, the U.S. Food and Drug Administration (FDA) approved Zepbound (tirzepatide) as the first-ever medication for moderate to severe obstructive sleep apnea (OSA) in adults with obesity. This approval marks a significant step forward in treating OSA, offering a new option for patients who have struggled with traditional treatments such as continuous … Read more